Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Davis UCSF
Dates
study started
completion around
Principal Investigator
by Jennifer Li, MD (ucdavis)

Description

Summary

Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DMEK versus Descemet Stripping Only (DSO) with adjunctive Ripasudil.

Official Title

Descemet Endothelial Thickness Comparison Trials (DETECT I & II)

Keywords

Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy, Ripasudil, DSO plus topical ripasudil 0.4%

Eligibility

You can join if…

Open to people ages 18 years and up

  • Dysfunctional endothelium from FECD with few guttata extending beyond 4.5 mm
  • Peripheral endothelial cell count >1500 cells/mm2
  • Good surgical candidate for either procedure as determined by the surgeon
  • Willingness and ability to undergo corneal transplantation
  • Willingness to consistently use study medications (i.e. ROCK-inhibitors)
  • Willingness to participate in follow-up visits
  • Age greater than 18 years

You CAN'T join if...

  • Other primary endothelial dysfunction such as PPMD
  • Any prior intraocular surgery other than cataract surgery
  • Cataract surgery within the last 3 months
  • >3 clock hours of ANY anterior or posterior synechiae
  • >1 quadrant of stromal corneal vascularization
  • Visually significant optic nerve or macular pathology
  • Fellow eye visual acuity <20/200
  • Pregnancy
  • Inability to comply with post-operative instructions (i.e. unable to position)
  • Hypotony (Intraocular pressure <10mmHg)
  • Peripheral anterior synechiae (iris to angle) in the angle greater than a total of three clock hours
  • Aphakia, anterior chamber IOL or scleral fixated IOL in study eye prior to or anticipated during EK
  • Pre-operative central sub-epithelial or stromal scarring that the investigator believes is visually significant and could impact post-operative stromal clarity assessment

Locations

  • University of California Davis accepting new patients
    Sacramento California 95817 United States
  • Stanford University accepting new patients
    Palo Alto California 94303 United States
  • Oregon Health & Science University accepting new patients
    Portland Oregon 97239 United States
  • Dartmouth-Hitchcock Medical Center accepting new patients
    Lebanon New Hampshire 03766 United States

Lead Scientist at University of California Health

  • Jennifer Li, MD (ucdavis)
    Professor, Ophthalmology, School of Medicine. Authored (or co-authored) 113 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Stanford University
ID
NCT05275972
Phase
Phase 3 Fuchs' Dystrophy Research Study
Study Type
Interventional
Participants
Expecting 60 study participants
Last Updated